The Journal of Infectious Diseases has published the results of this study with Dr. Felipe García from the Infectious Diseases Unit of IDIBAPS – Hospital Clinic, as first author and Dr. Teresa Gallart from the Immunology Laboratoy of the same centre as last author. The work counted on an international collaboration with teams from France, the Hôpital Pitié-Salpêtriére and the Université Pierre et Marie Curie in Paris/INSERM, and the USA, the National Institute of Cancer in Maryland.
A total of 24 patients participated in this double blind clinical trial, half of whom formed the control Group and who did not receive the vaccine. None of these patients received antiretroviral treatment and to enter into the study had to maintain a good T lymphatic blood load (>450 per mm3). The vaccine was personalized and was made from the dendritic cells of each patient sensitized in the laboratory against an inactive form of their own virus. We are looking at a cell therapy that in the ambit of IDIBAPS received support from the Cell Therapy programme of the University of Barcelona. The vaccine was administered in 3 dosis with an interval of 2 weeks between each one.
At the end of 24 weeks, it showed that the majority of patients had experienced a significant decrease in the viral load. This decrease was very significant is some of them but in no case did the virus become undetectable. However this is a very important improvement with respect to previous initiatives where with a similar vaccine there was a modest response in 30% of the treated patients. No therapeutic vaccine has achieved up to now the same level of response as in this study. A new clinical trial is underway testing the administration of the vaccine in conjunction with antiretroviral drugs to allow an improvement in the results.
The principal objective of therapeutic vaccines is to minimize the need for antiretroviral drug treatment. These treatments have improved enormously over the past few years and have become easy drugs to administer with few side effects. Although the daily administering is not ideal, there is no experience over the long term and it is not known if the treatment could bring about resistance. It aims to deal with the treatment of chronic patients for their whole life which currently is an important economic burden for the health system. The annual budget for antiretrovirals in Hospital Clinic is around 30 Million Euros. Furthermore the therapeutic vaccine is easy to produce and small administrations could be implemented in developing countries, too. To undertake this ambitious objective there has to be a continuing scientific and economic efforts in initiatives such as HIVACAT.
About HIVACAT
The HIVACAT AIDS vaccine research and development project is a joint private and public sector-funded consortium without precedent in Spain, placing our country to the fore of HIV and AIDS research internationally. Consisting of the two of most important and established AIDS research centres in the country, the IrsiCaixa Institute for AIDS Research and the AIDS and Infectious Diseases Service at Barcelona’s Hospital Clìnic, HIVACAT carries out research into the development of a new vaccine against HIV in coordination with ESTEVE, and with the support of the “La Caixa” Bank Foundation (“Fundació la Caixa”), the Department of Health and the Department of Innovation, Universities and Companies of the Generalitat de Catalunya, Catalonia’s autonomous government. This consortium is the first major attempt at establishing collaboration in this field between local government, researchers and companies.
In Spain, the project is co-directed by Dr Bonaventura Clotet from IrsiCaixa and Dr Josep Maria Gatell from Barcelona’s Hospital Clìnic. Both research centres are conducting research alongside 5,000 patients who benefit from both the rapid incorporation of new treatments developed directly in the two centres, and innovations achieved internationally. HIVACAT consists of a team of more than 60 scientists trained in prestigious international research centres such as the University of Harvard in the United States, l’Insitut Pasteur in Paris, and London’s Royal Free Hospital.